Q32 Bio’s Director Graysel David S. Buys More Shares, Stokes Confidence Amid Volatile Biotech Stock
Grayzel David S. exercises Q32 Bio’s newly granted stock option, adding 16,363 shares and signalling cautious long‑term confidence in the biotech’s gene‑correction platform.
4 minutes to read